China Daily Briefing

China announced a USD 2.2 trillion urban renewal plan targeting construction and property sectors — a massive fiscal and state-directed stimulus that is the direct driver of today's Property +2.32% sector gain. Urban renewal at this scale targets tier-2 and tier-3 city infrastructure replacement rather than new greenfield development, which means sustained demand for construction materials, property developers focused on existing asset renovation, and municipal bond issuance. For the broader property sector recovery thesis, this plan addresses the demand-creation gap that private developer credit constraints left behind — it's state-directed demand rather than organic buyer demand, but it's real capex.

China's Innovent Biologics signed a USD 10.5 billion deal with Pfizer covering 12 cancer drug trial programs — one of the largest China-US pharma licensing transactions on record and a landmark validation of China's biotech R&D capability. The deal structure (licensing out pipeline candidates to a global pharma) signals that Chinese oncology pipelines have reached global regulatory standards and that Pfizer is willing to pay a portfolio premium for early-stage China assets. For broader China biotech investors, this is the template deal: pipeline + regulatory approval pathway + Big Pharma distribution network is now a proven China biotech value-creation playbook.

Futu Holdings reported Q1 2026 profit down 61% year-on-year following a USD 272 million regulatory fine — a significant earnings impact that weighed on the fintech sector even as FUTU shares gained 1.93% on the session. The market's muted reaction to a 61% profit decline reflects that the fine was a known event; the forward question is whether Futu's trading volumes and fee income recover post-fine or whether regulatory scrutiny has durably chilled its core business. Futu's offshore brokerage model (serving Mainland Chinese investors through HK and international platforms) sits in a sensitive regulatory zone — any signal of new compliance requirements from Hong Kong's SFC or CSRC would be the real risk to watch.